References
- Stewart SA, Bertuch AA. The role of telomeres and telomerase in cancer research. Cancer Res 2010;70:7365–71.
- Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell 2002;2:257–65.
- Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. Nat Rev Drug Discov 2006;5:577–84.
- Corey DR. Telomeres and telomerase: from discovery to clinical trials. Chem Biol 2009;16:1219–23.
- Bhattacharya S, Chaudhuri P, Jain AK, et al. Symmetrical bisbenzimidazoles with benzenediyl spacer: the role of the shape of the ligand on the stabilization and structural alterations in telomeric G-quadruplex DNA and telomerase inhibition. Bioconjug Chem 2010;21:1148–59.
- Paul A, Maji B, Misra SK, et al. Stabilization and structural alteration of the G-quadruplex DNA made from the human telomeric repeat mediated by Troger's base based novel benzimidazole derivatives. J Med Chem 2012;55:7460–741.
- Herbert B, Pitts AE, Baker SI, et al. Inhibition of human telomerase in immortal human cells lead to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999;96:14276–81.
- Sun D, Thompson B, Cathers BE, et al. Inhibition human telomerase G-quadruplex-interactive compound. J Med Chem 1997;40:2113–2116.
- Autexier C, Lue NF. The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 2006;75:493–517.
- Hahn W, Stewart SA, Brooks MW, et al. Inhibition for telomerase limits the growth of human cancel cells. Nat Med 1999;5:1164–70.
- Li Y, Pan G, Chen Y, et al. Inhibitor of the human telomerase reverse trancriptase (hTERT) gene promoter induces cell apoptosis via a mitochondrial-dependent pathway. Eur J Med Chem 2018;145:370–8.
- Wang Y, Cheng FX, Yuan XL, et al. Dihydropyrazole derivatives as telomerase inhibitors: structure-based design, synthesis, SAR and anticancer evaluation in vitro and in vivo. Eur J Med Chem 2016;112:231–51.
- Chen YY, Wu XQ, Tang WJ, et al. Novel dihydropyrazole-chromen: design and modulates hTERT inhibition proliferation of MGC-803. Eur J Med Chem 2016;110:65–75.
- Barma DK, Elayadi A, Falck JR, et al. Inhibition of telomerase by BIBR 1532 and related analogues. Bioorg Med Chem Lett 2003;13:1333–6.
- Makhlouf Brahmi M, Portmann C, D'Ambrosio D, et al. Telomerase inhibitors from cyanobacteria: isolation and synthesis of sulfoquinovosyl diacylglycerols from Microcystis aeruguinosa PCC 7806. Chem Eur J 2013;19:4596–601.
- Sekaran V, Soares J, Jarstfer MB. Telomere maintenance as a target for drug discovery. J Med Chem 2014;57:521–38.
- Ruden M, Puri N. Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 2013;39:444–56.
- Gillis AJ, Schuller AP, Skordalakes E. Structure of the Tribolium castaneum telomerase catalytic subunit TERT. Nature 2008;455:633–7.
- Zheng QZ, Zhang XM, Xu Y, et al. Synthesis, biological evaluation, and molecular docking studies of 2-chloropyridine derivatives possessing 1,3,4-oxadiazole moiety as potential antitumor agents. Bioorg Med Chem 2010;18:7836–41.
- Brouwer AJ, Álvarez NH, Ciaffoni A, et al. Proteasome inhibition by new dual warhead containing peptide vinyl sulfonyl fluorides. Bioorg Med Chem 2016;24:3429–35.
- Alvarez NH, Langemheen HVD, Brouwer AJ, et al. Potential peptidic proteasome inhibitors by incorporation of an electrophilic trap based on amino acid derived a-substituted sulfonyl fluorides. Bioorg Med Chem 2017;25:5055–63.
- Kisselev AF, Van der Linden WA, Overkleeft HS. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 2012;19:99–115.
- Wang JQ, Yang MD, Wang Y, et al. Discovery of new chromen-4-one derivative as telomerase inhibitor through regulating expression of dyskerin. J Enzym Inhib Med Chem 2018; in press.
- Zha GF, Zheng QH, Leng J, et al. Palladium-catalyzed fluorosulfonylvinylation of organic iodides. Angew Chem Int Ed 2017;56:4849–52.